Patricia L. Morris

Array ( [id] => 15650279 [patent_doc_number] => 20200087669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683625 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15650275 [patent_doc_number] => 20200087667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683477 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711603 [patent_doc_number] => 20200102567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683417 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15590345 [patent_doc_number] => 20200071707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683524 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14220 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15590347 [patent_doc_number] => 20200071708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/683543 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16683543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868488 [patent_doc_number] => 20210161955 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2021-06-03 [patent_title] => COMPOSITIONS CONTAINING A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERACTIVATED CYTOKINE KILLER T CELLS AND METHODS FOR MAKING SAME [patent_app_type] => utility [patent_app_number] => 16/682422 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16682422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16868488 [patent_doc_number] => 20210161955 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2021-06-03 [patent_title] => COMPOSITIONS CONTAINING A CELL PRODUCT COMPRISING AN EXPANDED AND ENRICHED POPULATION OF SUPERACTIVATED CYTOKINE KILLER T CELLS AND METHODS FOR MAKING SAME [patent_app_type] => utility [patent_app_number] => 16/682422 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16682422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299538 [patent_doc_number] => 20210395377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF FIBROSIS [patent_app_type] => utility [patent_app_number] => 17/292102 [patent_app_country] => US [patent_app_date] => 2019-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22639 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 187 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17292102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18179247 [patent_doc_number] => 20230039976 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS [patent_app_type] => utility [patent_app_number] => 17/290705 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 170131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -156 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312962 [patent_doc_number] => 20210402010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => A COMBINATION THERAPY FOR TREATMENT OF THORACIC CANCER USING Ad-REIC/Dkk-3 AND A CHECKPOINT INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/290656 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4198 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297851 [patent_doc_number] => 20210393690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 17/290065 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 131441 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -167 [patent_words_short_claim] => 437 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548136 [patent_doc_number] => 20220119477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => TCR AND PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/288406 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15524843 [patent_doc_number] => 20200054727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/669622 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312839 [patent_doc_number] => 20210401887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE [patent_app_type] => utility [patent_app_number] => 17/289877 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24096 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213097 [patent_doc_number] => 20210346433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => LET-7 PROMOTES ANTI-TUMOR ACTIVITY OF CD8 T CELLS AND MEMORY FORMATION IN VIVIO [patent_app_type] => utility [patent_app_number] => 17/250988 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17250988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15738507 [patent_doc_number] => 20200108141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/661671 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16661671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18085553 [patent_doc_number] => 11535671 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Therapeutic and diagnostic methods for cancer [patent_app_type] => utility [patent_app_number] => 16/655495 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 34 [patent_no_of_words] => 55880 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214508 [patent_doc_number] => 20210347845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => COMPOSITIONS AND METHODS FOR SWITCHABLE CAR T CELLS USING SURFACE-BOUND SORTASE TRANSPEPTIDASE [patent_app_type] => utility [patent_app_number] => 17/284407 [patent_app_country] => US [patent_app_date] => 2019-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16298006 [patent_doc_number] => 20200283729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/599988 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 117403 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16599988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17290942 [patent_doc_number] => 20210386781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) [patent_app_type] => utility [patent_app_number] => 17/282287 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 472 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282287 [rel_patent_id] =>[rel_patent_doc_number] =>)